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Abstract
Introduction: In ICUs, both fluid overload and oliguria are common complications associated with increased
mortality among critically ill patients, particularly in acute kidney injury (AKI). Although fluid overload is an
expected complication of oliguria, it remains unclear whether their effects on mortality are independent of each
other. The aim of this study is to evaluate the impact of both fluid balance and urine volume on outcomes and
determine whether they behave as independent predictors of mortality in adult ICU patients with AKI.
Methods: We performed a secondary analysis of data from a multicenter, prospective cohort study in 10 Italian
ICUs. AKI was defined by renal sequential organ failure assessment (SOFA) score (creatinine >3.5 mg/dL or urine
output (UO) <500 mL/d). Oliguria was defined as a UO <500 mL/d. Mean fluid balance (MFB) and mean urine
volume (MUV) were calculated as the arithmetic mean of all daily values. Use of diuretics was noted daily. To
assess the impact of MFB and MUV on mortality of AKI patients, multivariate analysis was performed by Cox
regression.
Results: Of the 601 included patients, 132 had AKI during their ICU stay and the mortality in this group was 50%.
Non-surviving AKI patients had higher MFB (1.31 ± 1.24 versus 0.17 ± 0.72 L/day; P <0.001) and lower MUV (1.28 ±
0.90 versus 2.35 ± 0.98 L/day; P <0.001) as compared to survivors. In the multivariate analysis, MFB (adjusted hazard
ratio (HR) 1.67 per L/day, 95%CI 1.33 to 2.09; <0.001) and MUV (adjusted HR 0.47 per L/day, 95%CI 0.33 to 0.67;
<0.001) remained independent risk factors for 28-day mortality after adjustment for age, gender, diabetes,
hypertension, diuretic use, non-renal SOFA and sepsis. Diuretic use was associated with better survival in this
population (adjusted HR 0.25, 95%CI 0.12 to 0.52; <0.001).
Conclusions: In this multicenter ICU study, a higher fluid balance and a lower urine volume were both important
factors associated with 28-day mortality of AKI patients.
Introduction
Early and appropriate goal-directed fluid therapy is fun-
damental in acute resuscitation of critically ill patients
[1,2]; however, it is almost always associated with a cer-
tain degree of fluid overload (FO) [3,4], which promotes
tissue edema that could potentially contribute to pro-
gressive organ dysfunction [5,6].
There is a growing amount of evidence supporting the
relation between FO and unfavorable outcomes in criti-
cally ill patients. This has been demonstrated in general
ICUs [7] and in specific clinical settings, such as acute
lung injury/acute respiratory distress syndrome (ALI/
ARDS) [8,9], in patients undergoing abdominal surgery
[10,11], cardiac surgery [12] and in septic patients [13].
With regard to acute kidney injury (AKI) in particular,
multiple pediatric studies have shown that a greater FO at
the time of renal replacement therapy (RRT) is associated
with higher mortality [14-16]. In a small study of 81 adult
AKI patients who underwent RRT, a volume-related
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weight gain (VRWG) >10%, used as a surrogate for FO,
was similarly associated with poor outcomes [17]. An asso-
ciation between FO and higher mortality has also been
shown in critically ill patients with less severe forms of
AKI [18-21]. In this context, FO has emerged as a poten-
tial ‘biomarker’ in critical illness, and it has been proposed
that its prevention may be an important determinant of
survival, particularly in AKI [3].
Oliguria is a common situation in the ICU and is con-
sidered an early and sensitive biomarker of renal injury
because it may precede a creatinine-based diagnosis of
AKI [22,23]. Furthermore, in multicenter studies on cri-
tically ill patients with AKI, the presence of oliguria has
been associated with higher mortality [20,24-26]. Indeed,
the evidence points out that both FO and oliguria are
important predictors of mortality in critically ill patients.
Fluid accumulation is a logical and expected complica-
tion of oliguric AKI due to impaired water and sodium
excretion [20,27]. It remains unclear whether their
effects are independent of each other or if FO is merely
in the causal pathway between oliguria and death. Inter-
estingly, very few studies have adjusted for urine output
in the analysis on FO and mortality. In 81 AKI patients
requiring RRT, both oliguria and FO were independent
predictors of mortality [17] and in a post hoc analysis of
306 AKI patients from the Fluid and Catheter Treat-
ment Trial (FACTT), FO was shown to be indepen-
dently associated with mortality both in oliguric and
non-oliguric patients [19]. In a large multicenter Eur-
opean study [20] on critically ill patients with AKI, a
positive fluid balance was an important factor associated
with increased 60-day mortality, but there was no
adjustment for urine volume or oliguria.
The aim of the present study is to evaluate the impact
of both fluid balance and urine volume on outcomes
and determine whether they behave as independent pre-
dictors of mortality in adult ICU patients with AKI.
Materials and methods
Study design and data collection
We performed a secondary analysis of data from 601
patients enrolled in a prospective multicenter ICU cohort
study of adult patients (age ≥18 years) admitted to 10
ICUs from September 2009 to April 2010 (NEFROlogia e
Cura INTensiva (NEFROINT) Study), designed to describe
the epidemiology of AKI in Italian ICUs [28]. Detailed
methods of data collection have been previously described
[29]. Collected data included demographics, anthropo-
metrics, admission diagnosis, comorbidities, daily vital
signs and laboratory data to calculate automatically the
Acute Physiology and Chronic Health Evaluation II
(APACHE II) [30], the Simplified Acute Physiology Score
II (SAPS II) [31] and the Sequential Organ Failure Assess-
ment (SOFA) [32] scores. RRT details and mortality were
also reported. Furthermore, 24-hour urine output, worst
6-hour and worst 12-hour urine output, fluid balance and
use of diuretics were recorded daily. Furosemide was the
only diuretic used in all the centers. Fluid balance was cal-
culated daily as the difference between fluid intake and
fluid output. Fluid output included all body fluids, includ-
ing urine and, if applicable, dialysis ultrafiltrate. This study
was approved by the ethics committee of St. Bortolo Hos-
pital, Vicenza, Italy. Because of the anonymous and non-
interventional nature of the study, the ethics committees
of the participating study centers (see list below) waived
the need for informed consent.
Definitions
AKI was defined according to the renal SOFA score as a
creatinine >3.5 mg/dL or a urine output <500 mL/day, as
used by the Sepsis Occurrence in Acutely Ill Patients
(SOAP) study investigators [20]. Patients who received
RRT were assigned a renal SOFA score of 4, regardless of
the serum creatinine or urine output. AKI was considered
‘early’ if it occurred in the first two days of ICU admission
and ‘late’ if it occurred more than two days after ICU
admission [20]. Oliguria was defined as a urine output of
less than 500 mL/day. Mean fluid balance (MFB) and
mean urine volume (MUV) were calculated as the arith-
metic mean of the daily values during the patient’s ICU
stay. The SOFA score was expressed in two ways: total
score and the score without the renal component (non-
renal SOFA). For sensitivity analysis, we also defined AKI
using the Risk, Injury, Failure, Loss of kidney function and
End-stage kidney disease (RIFLE) consensus [33].
Statistical analysis
Continuous variables were expressed as both mean ± SD
and as median (IQR) and compared between any two
groups (for example, AKI versus non-AKI, survivors ver-
sus non-survivors, early versus late AKI and so on), using
the t-test or Mann-Whitney U test, as appropriate. Nor-
mality of distribution was evaluated by visual inspection
of histograms and by the Kolmogorov Smirnov test.
Categorical variables are expressed as number of cases
and proportion and compared with the Mantel-Haenszel
Chi-square test or the Fisher exact test.
To evaluate the influence of MFB and MUV on the
survival time of AKI patients, exploratory univariate ana-
lysis for several variables was first performed to identify
possible confounders associated with 28-day mortality. A
multivariable Cox regression analysis was then performed
using a forward stepwise selection method, criteria for
entry 0.05 and for removal 0.10. The assumption of pro-
portional hazards was checked graphically using log(-log
(survival probability)) plots and was found appropriate.
Variables considered for multivariable analysis were age,
gender, co-morbid disease, sepsis, non-renal SOFA, and
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MFB, as were used in a previous study [20], with the addi-
tion of MUV and diuretic use. Age, sepsis and diuretic use
were all significant on univariate analysis. APACHE II,
SAPS II, and total and non-renal SOFA scores were also
significant on univariate analysis, but the strongest associa-
tion with mortality was seen with non-renal SOFA, and
this was used in all multivariable models. We tested for
collinearity among all variables. From the Cox model,
hazard ratio (HR) and 95% CIs were generated. We also
performed a number of sensitivity analyses. First, since
MFB and MUV were found to be collinear, we repeated
the analysis using an interaction term MFB*MUV. Second,
we also expressed urine output as the presence of oliguria
anytime during the ICU stay and the duration of oliguria
(defined as the proportion of ICU days complicated by
oliguria) as an alternate representation of urine volume in
the models. Third, diuretic use was also expressed as
duration of diuretic use (defined by the proportion of ICU
days in which diuretics were used). The 28-day survival by
timing of AKI, oliguria and diuretic use were additionally
evaluated graphically using the Kaplan-Meier product
limit survival plot. All statistical analysis was performed
using the SPSS 19.0 (SPSS Inc, Chicago, IL, USA) software
package, with a two-sided P value <0.05 considered as
statistically significant.
Results
Study population
Of the 601 patients enrolled in the NEFROINT study [28],
25 were excluded because of the presence of end-stage
renal disease on chronic RRT and three other patients
were excluded because of incomplete data on fluid balance
and urine output, leaving 573 patients for analysis. Charac-
teristics of the entire cohort are shown in Additional file 1,
Table S1. The mean age was 63.0 ± 17.3 years and 59.5%
were men. All-cause 28-day mortality was 21.8% and
mean ICU length of stay was 10.1 ± 12.0 days. Of these
patients, 132 (23%) developed AKI.
Acute kidney injury
AKI patients were older, more likely to be diabetic and to
have sepsis or a cardiovascular diagnosis at ICU admission
and higher illness severity scores than non-AKI [see
Additional file 1, Table S1]. MFB was higher (0.7 ± 1.2
versus 0.5 ± 1.1 L/day; P = 0.008) and MUV was lower
(1.8 ± 1.1 versus 2.6 ± 1.3 L/day; P <0.001) in the AKI
group. Diuretics were used more commonly on AKI
patients and for a larger proportion of ICU days (Table 1).
Mortality was higher among AKI patients (50% versus
13.4%; P <0.001) and ICU stay was longer.
AKI patient characteristics according to outcome are
shown in Table 2. Non-surviving AKI patients were older,
had higher illness severity scores and were more likely to
be septic. The MFB was higher (1.3 ± 1.2 versus 0.2 ± 0.7
L/day; P <0.001) and the MUV was lower (1.3 ± 0.9 versus
2.3 ± 1.0 L/day; P <0.001) among non-survivors. Oliguria
was also more common in non-survivors (83.3% versus
54.5%; P = 0.001) and persisted for a larger proportion of
the ICU stay (35.5 ± 34.5% versus 13.6 ± 21.9%; P <0.001).
Early AKI was present in 83 patients (62.9% of the AKI
group) and was associated with higher illness severity
scores, lower MUV (1.6 ± 1.1 versus 2.2 ± 0.9 L/day;
P <0.001), a larger proportion of days of oliguria (32.3%
versus 11.5%, P <0.001) and fewer RRT-free days, but a
shorter ICU stay than late AKI [see Additional file 1,
Table S2]. The MFB, the proportion of days with diuretics
and the mortality were not different between the groups.
As expected, oliguric patients had a higher MFB (0.9 ±
1.3 versus 0.4 ± 1.0 L/day; P <0.001), tended to receive
diuretics more often (73.6% versus 62.7%; P = 0.06), had
higher mortality (60.4% versus 14.4%; P <0.001) and
longer ICU stay (15.5 ± 15.8 versus 9.3 ± 10.9; P <0.001)
than non-oliguric patients.
Mean fluid balance, mean urine volume and mortality
In general, non-survivor AKI patients had significantly
higher MFB compared to survivors (Figure 1). When ana-
lyzing the subgroups separately by AKI timing, the pre-
sence of oliguria and the use of diuretics, the same results
were observed. The MUV was significantly lower among
non-survivors overall, and in most of the subgroups, except
in non-oliguric patients. Figure 2 demonstrates the pattern
of cumulative fluid balance among survivors and non-sur-
vivors in the first seven days in the ICU. Non-survivors
consistently had higher mean cumulative fluid balance
throughout the ICU stay and the magnitude of the differ-
ence between the groups increased with each additional
day.
The 28-day survival was significantly better among non-
oliguric patients (Figure 3; P <0.044) and in patients trea-
ted with diuretics (Figure 4; P = 0.001). The 28-day survi-
val was similar between early and late AKI (not shown,
P = 0.16 on log rank test).
On multivariate Cox regression analysis (Table 3), both
MFB and MUV were independent predictors of 28-day
mortality (MFB, adjusted HR 1.67, 95%CI 1.33 to 2.09 per
L/day; P <0.001 and MUV, adjusted HR 0.47, 95%CI 0.33
to 0.67 per L/day; P <0.001, Model 1). Interestingly, the
use of diuretics appeared to be associated with a lower risk
of death in both unadjusted and adjusted analysis
(adjusted HR 0.25, 95%CI 0.12 to 0.52; P <0.001). Colli-
nearity was observed between MFB and MUV, and we
performed a second model including the interaction
between the two (MFB*MUV). In this model, the interac-
tion term was significant; the effect of MFB was somewhat
attenuated, while the effect of MUV was accentuated. Of
interest, higher non-renal SOFA scores were significantly
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associated with increased mortality on univariate analysis
(HR 1.18, 95CI% 1.10 to 1.27; P <0.001), but this was no
longer significant on multivariable analysis (HR 1.04, 95CI
% 0.96 to 1.14; P = 0.35).
In terms of sensitivity analyses [see Additional file 1,
Table S3], qualitatively similar results were seen when
MUV was alternatively expressed as presence of oliguria
(adjusted HR 1.86, 95%CI 1.50 to 2.32 for MFB, and
adjusted HR 1.35, 95%CI 0.67 to 2.71 for oliguria) or
duration of oliguria (adjusted HR 1.72, 95%CI 1.37 to
2.15 for MFB, and adjusted HR 1.01, 95%CI 1.003 to
1.02 for %ICU days with oliguria), and when diuretic
usage was expressed as duration of diuretics (adjusted
HR 1.73, 95%CI 1.38 to 2.18 for MFB and adjusted HR
0.99, 95%CI 0.98 to 0.99 for %ICU days on diuretics).
Furthermore, results were also similar when AKI was
defined using RIFLE criteria (n = 378 AKI patients;
crude mortality 28.8%). The adjusted HR for MFB was
1.51, 95%CI 1.31 to 1.74 L/day; P <0.001 and for MUV
was 0.48, 95%CI 0.38 to 0.62 L/day; P <0.001 in this
sensitivity analysis (Table 4).
Discussion
Using data from a multicenter ICU cohort [28], we exam-
ined the influence of fluid balance and urine volume on
outcomes among critically ill patients with AKI. The key
findings of this study are: first, AKI patients had higher
MFB, lower MUV, and a higher mortality than non-AKI
patients; second, MFB was significantly higher in non-sur-
vivors in all AKI patients, and consistently higher across
various subgroups (early and late AKI, oliguric and non-
oliguric, use and non-use of diuretics, Figure 1); third,
MUV was lower in non-survivors in all subgroups, except
non-oliguric patients; finally, both MFB and MUV were
significantly associated with increased 28-day mortality in
AKI patients, and their interaction was significant as well.
Our results are consistent with prior studies on criti-
cally ill patients, both without and with AKI. In non-AKI
studies, a positive fluid balance was strongly associated
with increased mortality and other unfavorable outcomes
in some subgroups of ICU patients, including worse lung
function, longer duration of mechanical ventilation,
increased post-operative complications and longer ICU
stay [7-13]. Among adult AKI patients in particular, Van
Biesen et al. [21] showed that additional fluid loading not
only failed to improve renal function, but was also asso-
ciated with worsening of respiratory function. The Pro-
gram to Improve Care in Acute Renal Disease (PICARD)
group [18] concluded that fluid weight gain >10% in AKI
patients was associated with higher mortality and that
the increase in mortality rate was proportional to the
degree of fluid accumulation. In a study with 1,120 ICU
patients with AKI, the authors showed that the MFB was
an independent predictor of mortality on multivariate
analysis (adjusted HR 1.21, 95%CI 1.13 to 1.28; P <0.001)
[20]. However, these three studies did not adjust for
urine volume in their models.
An important finding in the present study is that fluid
balance and urine volume were both strong and significant
predictors of mortality, even accounting for their interac-
tion. We reproduced the analysis performed in AKI
patients from a multicenter European ICU cohort [20] and
extended it by adding the variable urine volume to the
analysis. Our findings confirmed the association of both
FO (adjusted HR per L/day of MFB 1.67, 95%CI 1.33 to
2.09; P <0.001) and reduced urine volume (adjusted HR
per L/day of MUV 0.47, 95%CI 0.33 to 0.67; P <0.001)
with adverse outcomes. Qualitatively similar findings were
obtained even when the urine volume was expressed as
the presence of oliguria or duration of oliguria, implying
that FO is not merely an intermediate in the pathway
between lower urine output and mortality. This relation is
not well-explored in the literature. To our knowledge,
only two adult AKI studies have adjusted for urine output
in their analysis of FO and outcomes. In a cohort of 81
adult critically ill patients with severe AKI requiring RRT,
the authors examined the effect of oliguria, VRWG used
as a measure of FO, sepsis and APACHE II score in the
multivariate model [17]. Both oliguria and VRWG ≥10%
were predictors of 30-day mortality (adjusted odds ratio
(OR) 3.04, 95%CI 1.10 to 8.36 and adjusted OR 2.71, 95%
CI 1.05 to 6.99, respectively). In the aforementioned
Table 1 Fluid balance, urine volume and diuretic use by presence or absence of AKI.
All (number = 573) AKI (number = 132) Non-AKI (number = 441) P
Mean fluid balance/24hours (L) 0.52 ± 1.11
0.40 (0.04 to 0.97)
0.74 ± 1.16
0.48 (0.02 to 1.26)
0.45 ± 1.09
0.38 (-0.05 to 0.86)
0.008
Mean urine volume/24hours (L) 2.43 ± 1.31
2.39 (1.66 to 3.06)
1.81 ± 1.08
1.88 (0.87 to 2.73)
2.62 ± 1.32
2.54 (1.86 to 3.11)
<0.001
Use of diuretics (%) 365 (63.7%) 102 (77.3%) 263 (59.6%) <0.001
Duration of diuretic use (days) 5.3 ± 8.5
2 (0 to7)
8.3 ± 11.3
4 (1 to 10)
4.4 ± 7.2
2 (0 to 6)
<0.001
% ICU days with diuretics 43.2 ± 39.6%
42.9 (0 to 80.5%)
51.0 ± 37.6%
51.9 (8.7 to 87.5%)
(40.9 ± 39.9%)
38.5 (0 to 78.4%)
0.010
AKI, acute kidney injury.
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Table 2 AKI patient characteristics by outcome.
All AKI (number = 132) Survivors (number = 66) Non-Survivors (number = 66) P
Male gender 84 (63.6%) 43 (34.8%) 41 (62.1%) 0.86
Age (years) 66.3 ± 14.1
68.5 (38 to 57.5)
63.1 ± 15.6
64 (52.8 to 76)
69.5 ± 11.7
74 (61 to 78.3)
0.015
ICU Admission
SAPS II 50.0 ± 14.5
48 (38 to 57.5)
46.3 ± 13.5
42 (37 to 52.8)
53.7 ±14.6
51.5 (43.8 to 61.3)
0.001
SOFA 8.0 ± 4.1
7 (5 to 11)
6.8 ± 3.6
7 (4 to 9.3)
9.2 ± 4.3
8.5 (6 to 12)
0.002
Non-renal SOFA 6.6 ± 3.5
6 (4 to 9)
5.4 ± 2.9
5 (3 to 7)
7.8 ± 3.6
7 (5 to 11)
<0.001
APACHE II 22.3 ± 8.4
21 (16 to 28)
20.3 ± 7.7
19 (15 to 25.3)
24.4 ± 8.6
24 (16.8 to 31)
0.006
Vasoactive therapy 56 (42.4%) 21 (31.8%) 35 (53.0%) 0.022
Mechanical ventilation 96 (72.7%) 44 (66.7%) 52 (78.8%) 0.17
Serum creatinine (mg/dL) 2.3 ± 2.0
1.45 (0.9 to 3.2)
2.3 ± 2.0
1.4 (0.9 to 3.1)
2.4 ± 2.1
1.5 (0.8 to 3.3)
0.99
Comorbid diseases
Diabetes 41 (31.1%) 20 (30.3%) 21 (31.8%) 1
Cardiovascular 66 (50.0%) 31 (47.0%) 35 (53.0%) 0.60
Hypertension 67 (50.8%) 29 (43.9%) 38 (57.6%) 0.16
Chronic kidney disease 19 (14.4%) 10 (15.2%) 9 (13.6%) 1
Metastatic carcinoma 4 (3.0%) 3 (4.5%) 1 (1.5%) 0.62
Hematologic malignancy 6 (4.5%) 2 (3.0%) 4 (6.1%) 0.68
Category of ICU admission diagnosis
Respiratory 44 (33.3%) 20 (30.3%) 24 (36.4%) 0.58
Neurologic 15 (11.4%) 9 (13.6%) 6 (9.1%) 0.59
Trauma 8 (6.1%) 5 (7.6%) 3 (4.5%) 0.72
Cardiovascular 25 (18.9%) 12 (18.2%) 13 (19.7%) 1
Sepsis 15 (11.4%) 6 (9.1%) 9 (13.6%) 0.59
ICU course
Sepsis 61 (46.2%) 23 (34.8%) 38 (57.6%) 0.014
Early AKI (%) 83 (62.9%) 39 (59.1%) 44 (66.7%) 0.47
Mean fluid balance/24hours (L) 0.74 ± 1.16
0.48 (0.02 to 1.26)
0.17 ± 0.72
0.02 (-0.17 to 0.48)
1.31 ± 1.24
1.09 (0.49 to 1.85)
<0.001
Oliguria 91 (68.9%) 36 (54.5%) 55 (83.3%) 0.001
Duration of oliguria (days) 2.8 ± 5.9
1 (0 to 3)
1.6 ± 4.0
1 (0 to 1)
4.0 ± 7.2
2 (1 to 4)
<0.001
% of ICU days with oliguria 24.6 ± 30.8%
11.9% (0 to 37.1%)
13.6 ± 21.9%
2.8% (0 to 20.7%)
35.5 ± 34.5
25% (6.7 to 62.0%)
<0.001
Mean urine volume/24hour(L) 1.81 ± 1.08
1.88 (0.87 to 2.73)
2.35 ± 0.98
2.49 (1.61 to 3.12)
1.28 ± 0.90
1.22 (0.55 to 1.96)
<0.001
Use of diuretics (%) 102 (77.3%) 55 (83.3%) 47 (71.2%) 0.15
Duration of diuretic use (days) 8.3 ± 11.3
4 (1 to 10.8)
10.3 ± 13.5
4.5 (1 to 13)
6.4 ± 8.3
3 (0 to 10)
0.11
% of ICU days receiving diuretics 51.0 ± 37.6
51.9% (8.7 to 87.5%)
56.2 ± 36.7%
55.6% (20 to 93.0%)
45.9 ± 38.1%
46.9% (0 to 82.6%)
0.11
Outcomes
RRT 67 (50.8%) 31 (47.0%) 36 (54.5%) 0.49
Duration of RRT (days)(% of ICU days) 3.2 ± 6.9
1 (1 to 3)
2.2 ± 4.3
0 (0 to 3)
4.1 ± 8.7
1.5 (0 to 5)
0.14
% of ICU days on RRT 23.3 ± 31.3%
3.9% (0 to 45.2%)
15.4 ± 24.1%
0% (0 to 21.6%)
31.1 ± 35.6%
6.7% (0 to 66.7%)
0.03
RRT free days 12.1 ± 13.9
8 (3 to 16.8)
15.1 ±17.1
9 (3 to 23.3)
9.1 ± 8.8
6.5 (2.8 to 13)
0.06
Length of ICU stay (days) 15.3 ± 16.3
10 (5 to 20)
17.4 ± 18.7
11.5 (5 to 24)
13.2 ±13.2
9 (4 to 19.3)
0.45
AKI, acute kidney injury; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; APACHE II, Acute Physiology and Chronic
Health Evaluation II; RRT, renal replacement therapy.
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FACTT study, the association between fluid balance and
mortality was significant in patients both with oliguria
(HR per L/day of MFB 1.77, 95%CI 1.27 to 2.45) and with-
out oliguria (HR per L/day of MFB 1.61, 95%CI 1.27 to
2.45) during the initial seven days after randomization
[19]. Our findings are consistent with these studies.
Furthermore, we observed that the interaction between
fluid balance and urine volume was statistically significant,
Figure 1 Mean fluid balance (A) and mean urine volume (B) in survivors and non-survivors. *P <0.05; **P <0.001. AKI, acute kidney injury.
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Figure 2 Cumulative fluid balance in survivors and non-survivors in the first seven days of ICU stay (mean ± SEM). *P =0.015; **P <0.01.
SEM, standard error of the mean.
Figure 3 Survival curve for 28-day mortality by the presence or absence of oliguria in the ICU.
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and still MFB and MUV individually remained predictors
of 28-day mortality.
The association between oliguria and worse outcomes
in AKI patients is well recognized [4,22]. In our study,
the survival of non-oliguric patients was significantly
better when compared to oliguric patients (Figure 3),
but in both groups non-survivors had significantly
higher MFB (Figure 1). Similarly to other authors
[20,25], we did not find significant differences in mortal-
ity between patients who developed early or late AKI
(not shown, P = 0.16 on log rank test) but again, non-
survivors in both groups presented significantly higher
MFB and lower MUV.
An interesting finding in the present study is that the
use of diuretics was inversely associated with mortality,
and this effect persisted after adjustment for MFB and
MUV (adjusted HR 0.25, 95%CI 0.12 to 0.52), suggesting
that the diuretic in itself may exert a protective effect.
This differs from the FACTT study, in which post-AKI
furosemide use had a protective effect on 60-day mortal-
ity on univariate analysis, but not when adjusted for
fluid balance [19]. The role of diuretics in AKI remains
controversial. While three meta-analyses [34-36] have
demonstrated a lack of association between diuretics
and mortality, only two of the included studies enrolled
ICU patients. Two observational studies in ICU settings
Figure 4 Survival curve for 28-day mortality by the use or non-use of diuretics in the ICU.
Table 3 Cox regression analysis for 28-day mortality.
Unadjusted Adjusted
Model 1 Model 2
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Mean fluid balance (L/day) 1.99 (1.68 to 2.36) <0.001 1.67 (1.33 to 2.09) <0.001 1.33 (1.002 to 1.77) 0.0048
Mean urine volume (L/day) 0.38 (0.29 to 0.51) <0.001 0.47 (0.33 to 0.67) <0.001 0.33 (0.21 to 0.52) <0.001
Diuretic use 0.40 (0.23 to 0.70) 0.001 0.25 (0.12 to 0.52) <0.001 0.26 (0.13 to 0.53) <0.001
Diabetes 1.16 (0.68 to 1.98) 0.58 2.16 (1.09 to 4.26) 0.027 2.08 (1.06 to 4.08) 0.033
Hypertension 1.76 (1.06 to 2.94) 0.03 2.18 (1.12 to 4.22) 0.021 2.17 (1.12 to 4.24) 0.023
MFB*MUV - - - - 1.53 (1.16-2.01) 0.003
Variables considered for model 1 included age, gender, co-morbid diseases (diabetes, hypertension and cardiovascular disease), non-renal SOFA, sepsis, mean
fluid balance, mean urine volume and diuretic use. In model 2, MFB*MUV (interaction term between MFB and MUV) was also included. Only significant variables
are shown in the table. HR, hazard ratio; MFB, mean fluid balance; MUV, mean urine volume.
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showed conflicting results. The PICARD Study Group con-
cluded that diuretic use increased the risk of death or non-
recovery of renal function (OR 1.77, 95%CI 1.14 to 2.76)
[37]. In contrast, the Beginning and Ending Supportive
Therapy for the Kidney (BEST Kidney) investigators did
not find a significant association between diuretic use and
mortality (adjusted OR 1.21, 95%CI 0.96 to 1.5) [38]. Loop
diuretics have effects that could be potentially beneficial in
preventing or minimizing the severity of AKI. They reduce
the oxygen demand and prevent hypoxic damage, and furo-
semide has been shown to improve renal hemodynamics,
attenuate ischemic-related renal angiogenesis and reduce
ischemic-induced apoptosis in animal models [39-41]. A
pilot phase II randomized, blinded, placebo-controlled trial
comparing furosemide to placebo in ICU patients with
early AKI is in progress [42]; this study aims to compare
the efficacy and safety of furosemide versus placebo on the
progression of AKI severity and fluid balance. The results
of this trial will help us to understand better the role of
diuretics in AKI in the critical care setting.
Our study has important strengths including its multi-
center design that contributes to reduce practice bias. The
depth of data collection permitted the exploration of the
effects of duration of oliguria and diuretic use, which con-
firmed the results of the main analysis. Our study also
extends this continuous association of fluid balance,
decreased urine volume and death to critically ill adults
meeting the consensus definition for AKI (RIFLE). How-
ever, we recognize some limitations. Because of the obser-
vational nature of the study, we cannot establish a causal
relationship between MFB, MUV and mortality. The mod-
est sample size precluded extensive subgroup analysis and
may have resulted in underestimation of the impact of
known risk factors, such as SOFA score, on multivariable
analysis. We did not collect data on actual diuretic dose,
but the proportion of ICU days in which diuretics were
used can be considered a reasonable surrogate. It is possi-
ble that the type of fluid (that is, colloid versus crystalloid,
parenteral versus enteral), aside from the volume, influ-
ences outcomes. Unfortunately, this information was not
available in our own study or in previous investigations on
FO [9,13]. We believe this is an important issue that needs
to be clarified with future studies. Nevertheless, our find-
ings are consistent across the multiple sensitivity analyses
performed and the association between fluid balance,
urine volume and mortality appears robust.
Conclusions
In summary, both fluid balance and urine volume were
found to be independent predictors of mortality in adult
critically ill patients with AKI. Of interest, diuretic use
appeared to be independently associated with better survi-
val in this study. The results of an ongoing phase II rando-
mized controlled trial on diuretics in early AKI will help
clarify this issue.
Key messages
• In this multicenter observational study in ICU
patients with AKI, non-survivors presented higher
MFB (1.3 ± 1.2 versus 0.2 ± 0.7 L/day; P <0.001) and
lower MUV (1.3 ± 0.9 versus 2.3 ± 1.0 L/day). Both
higher fluid balance and a lower urine volume were
shown to be independent predictors of 28-day mortal-
ity in this AKI population.
• The use of diuretics was associated with better
survival.
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di Napoli, Naples; University of Rome “La Sapienza”,
Rome; Vita-Salute San Raffaele University, San Raffaele
Scientific Institute, Milan; A.O.U.I. University of Verona,
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Additional material
Additional file 1: Table S1. Patient characteristics by presence or
absence of AKI. Table S2: Patient characteristics by early or late AKI. Table
S3: Sensitivity analysis using surrogates for mean urine volume and
diuretic use. Variables considered for the final model included age,
gender, co-morbid diseases, non-renal SOFA, sepsis, mean fluid balance,
mean urine volume and diuretic use. For sensitivity analysis mean urine
volume was replaced by either presence of oliguria or proportion of ICU
Table 4 Sensitivity analysis considering presence of AKI according to RIFLE classification.
Unadjusted Adjusted
HR (95% CI) P HR (95% CI) P
Mean fluid balance/24hours (L) 1.74 (1.56 to 1.95) <0.001 1.51 (1.31 to 1.74) <0.001
Mean urine volume/24hours (L) 0.39 (0.32 to 0.48) <0.001 0.48 (0.38 to 0.62) <0.001
Diuretic use 0.34 (0.22 to 0.52) <0.001 0.31 (0.19 to 0.51) <0.001
Diabetes 1.36 (0.88 to 2.10) 0.17 1.75 (1.08 to 2.85) 0.023
Variables considered for the model included age, gender, co-morbid diseases (diabetes, hypertension and cardiovascular disease), non-renal SOFA, sepsis, mean
fluid balance, mean urine volume and diuretic use. Only significant variables are shown in the table. AKI, acute kidney injury; HR, hazard ratio; RIFLE, Risk of renal
dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function and End-stage kidney disease.
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days with oliguria as surrogates for mean urine volume; and diuretic use
was substituted by proportion of ICU days receiving diuretics. AKI, acute
kidney injury; SOFA, sequential organ failure assessment.
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